Biopeople

Science and finance expert

Science and finance expert

08.07.2014 - Will Lewis has joined Uniqure’s supervisory board in June 2014. The human gene therapy specialist company expects to profit from Lewis’ expertise in both scientific and financial aspects of management as well as experience in orphan diseases.

Will Lewis has more than 20 years of executive experience in the pharmaceutical and finance industries both in the US and internationally. He served as president and CEO and as a member of the Board of Directors of Insmed, a US biopharma company specialised in inhalation therapies for orphan lung diseases. He co-founded Aegerion Pharmaceuticals, where he also filled the role of president and chief financiel officer. Prior to Aegerion, Lewis spent 10 years working in the U.S. and Europe in investment banking for JP Morgan, Robertson Stephens and Wells Fargo.

Lewis also serves as a member of the board of directors of Oberlin College and is a member of the Visiting Committees of the Weatherhead School of Management of Case Western Reserve University and The Hawken School. Jörn Aldag, CEO of uniQure, commented “[Lewis’] exceptional experience in the field of orphan diseases as well as his broad knowledge of the US and European financial markets will be of high value to the company.”

20.05.2014 Alessandra Cervino has joined Paris-based metagenomics specialist Enterome Bioscience SA as Head of Discovery.

Michael Guez

The 38-old reseacher brings the firm over 15 years of experience in the discovery and development of genetic and genomic biomarkers. Before joining Enterome, Cervino was VP R&D and Biostatistics at TCLand Expression, Head of Statistical Sciences at Scripps Florida, and group leader in statistical genetics at Rosetta Inpharmatics, a subsidiary of Merck & Co.

15.05.2014 ADC specialist Glythera (UK) has named Ian Evetts as its new Commercial Director.

Glythera

Evett brings in more than 20 years experience in the pharmaceutical industry with a track record of senior strategic and operational roles, among them Managing Director at Atebion BDS Ltd., Strategic Advisor at Bionure and Business Development and Portfolio Director at AstraZeneca. As Commercial Director of Glythera, he will provide strategic advice on developing the company’s technologies and therapies.

13.05.2014 Isarna Therapeutics GmbH (Munich) has named Elizabeth Czerepak to lead the company’s new office location in New York City as Chief Financial Officer and Chief Business Officer.

Isarna Therapeutics

Czerepak has a track record of 21 years in the biopharma industry and nine years as a venture capital investor at JP Morgan and Bear Stearns. She has served in various executive-level finance, licensing and corporate development positions, most recently as Chief Financial Officer and Principal Accounting Officer at Cancer Genetics, Inc. Prior to CGI, Czerepak worked at BASF Pharma (Knoll), Hoffmann-La Roche and Merck & Co.

06.05.2014 The European Food Safety Authority’s Management Board has nominated Dr. Bernhard Url as EFSA’s next Executive Director.

EFSA

Following the departure of former Director Catherine Geslain-Lanéelle, Url has been EFSA’s acting Executive Director since the autumn of 2013. A qualified veterinarian by training, he brings high-level management experience from public and private food-safety organisations to the role, most recently as Managing Director for the Austrian Agency for Health and Food Safety (AGES). Until March 2012, Url served as a member of EFSA’s Management Board.

29.04.2014 Canbex Therapeutics Ltd has hired Alberto Lledó as its new Chief Medical Officer.

Canbex SL

Lledó will lead Canbex’s preparations in proof-of-concept trials for VSN16R, a small molecule for the treatment of spasticity in multiple sclerosis. Lledó is a Senior Consultant Neurologist at the Clínica Creu Blanca (Barcelona), and spent sixteen years at Eli Lilly. He will take over as Chief Medical Officer from Dr. Miroslav Ravic, who is guiding the company through the completion of its Phase I study. 

24.04.2014 Roche’s pRED unit has a new head of oncology and translational research.

Vanderbilt University Medical Center/Susan Urmy

William Pao, currently director at the Hematology-Oncology division and Personalised Cancer Medicine unit at Vanderbilt University Medical Center, will lead Roche’s discovery, translational medicine and early development of innovative oncology medicines. Pao, who has focused on academic clinical research in the past, is one of the world’s top oncology experts.

17.04.2014 Irish antibody developer Prothena Corporation plc has named Tara Nickerson as its Chief Business Officer.

Prothena Corp.

Previously she held the position of Head of Corporate and Business Development at the company, where she was instrumental during Prothena’s demerger from Elan and Prothena’s worldwide collaboration with Roche to develop and commercialise antibodies that target alpha-synuclein. Prior to Elan, Nickerson was a senior scientist at Celera Genomics (Axys Pharmaceuticals). 

15.04.2014 Geneva-based antibody developer Novimmune SA has appointed Andrew Oakley as its new CFO.

Novimmune

The finance expert has been the CFO and Vice President of Actelion Pharmaceuticals U.S., Inc. since January of 2003. Prior to that, he held executive positions in major multinational building material companies, and spent several years as an equity analyst with banks in Australia, the UK and the US. Oakley has been a member of the Australian Institute of Chartered Accountants since 1987.

08.04.2014 Germany’s Merck KGaA (Darmstadt) has hired the former head of Boehringer Ingelheim’s biopharmaceuticals development team to lead its biosimilar unit, which was set up in 2012.

Merck

Prior to the stint at Boehringer, Simon Sturge was CEO of Dutch biotech OctoPlus NV, and he also acted as CEO of Vernalis plc (UK). In the past, Sturge has held several roles of increasing seniority – from Business Development, Marketing and Operations to CEO at Lonza Biologics, as well as at Celltech Biologics and at AstraZeneca. The native of Britain was awarded the UK Mediscience CEO of the Year award in 2005. Sturge succeeds Thierry Hulot, who created Merck’s biosimilars unit and took over responsibility for Global Manufacturing & Supply for the Merck Serono division at the end of 2013. Along with Sturge, Merck has also strengthened its team internally with Friederike Rotsch, who has now taken over as chief legal advisor. 

27.03.2014 Ghent-based AgroSavfe BV has added to its management team Maria Abad-Molina new Head of Product & Business Development and Dr. Miguel De Bolle (Photo) as Head of Research.

AgroSafve

While Bolle will head R&D to advance the company's Agrobody-technology platform for the development of innovative formulations for the sustainable use of crop protection products, Abad-Molina will be responsible for product development and registration at the company. A trained agronomical engineer who holds an Executive MBA, Abad--Molina has more than 20 years of experience in the crop protection and plant biotech-nology industries. Before joining the AgroSavfe management team, she was on the management team of BASF Plant Science subsidiary CropDesign, where she led global activities for placing plant protection products in the market, including the firm's top herbicide in terms of sales.

Vorherige Seite2/19Nächste Seite

Stock list

All quotes

TOP

  • CHRONTECH PHARMA (S)0.08 SEK14.29%
  • PROTHENA PLC (IE)18.44 USD6.84%
  • WILEX (D)3.28 EUR5.47%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • HYBRIGENICS (F)1.71 EUR-8.56%

TOP

  • WILEX (D)3.28 EUR349.3%
  • SANTHERA (CH)69.50 CHF114.8%
  • ADDEX (CH)4.21 CHF92.2%

FLOP

  • MERCK KGAA (D)63.45 EUR-51.0%
  • THROMBOGENICS (B)8.55 EUR-47.3%
  • VERONA PHARMA (UK)1.12 GBP-46.2%

TOP

  • SANTHERA (CH)69.50 CHF3410.1%
  • GW PHARMACEUTICALS (UK)415.25 GBP756.2%
  • SKYEPHARMA PLC (UK)260.00 GBP314.3%

FLOP

  • EVOCUTIS (UK)0.21 GBP-92.2%
  • CYTOS (CH)0.27 CHF-92.1%
  • THROMBOGENICS (B)8.55 EUR-72.5%

No liability assumed, Date: 21.07.2014


Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...

Current issue

All issues

Product of the week

Products

Events

All Events